FDA Class I Recalls at a 15-Year Peak: What 44 Active Campaigns Mean for Product Liability Files
The FDA's Center for Devices and Radiological Health reported that Class I medical device recalls reached a 15-year peak in 2026, with 44 individual recall campaigns active in recent weeks. A Class I designation means the agency has determined there is a reasonable probability the device will cause serious adverse health consequences or death. Each such designation is, in effect, a potential product-liability case file waiting for a plaintiff attorney to open it.
GAO report GAO-26-107619 flagged significant oversight gaps in recall-process management, including inadequate post-market surveillance and slow corrective-action timelines. For PI firms with active device-injury intakes, the GAO findings supply both a regulatory negligence theory and a discoverable paper trail. The report specifically questioned whether CDRH is adequately tracking manufacturer compliance with recall remediation timelines, a gap that plaintiffs have historically used to support punitive damages claims where the manufacturer had actual or constructive notice of a defect.
PI firms handling device injury intakes should cross-reference active Class I recall campaigns against client injury dates; a matching recall campaign substantially strengthens a strict-liability manufacturing-defect theory and may also support a failure-to-warn claim if the recall predates the plaintiff's injury.
Nuclear Verdicts Are Remaking the Med-Mal Insurance Market
The Homewood Insurance Group 2026 Medical Malpractice Market Update confirmed that med-mal insurance is in its seventh consecutive year of premium hardening. Roughly 39.9% of premiums rose year-over-year in 2025, and the primary driver is claim severity rather than claim frequency. Nuclear verdicts, defined as jury awards exceeding $10 million, increased 52% between 2023 and 2024, with the top-50 verdicts for the 2025-2026 cycle averaging $56 million, a record high.
For plaintiffs' counsel, the severity numbers carry a direct tactical implication: defendant carriers are now reserving at much higher levels even for claims that previously settled in the single-digit millions. That recalibration sometimes creates earlier-than-expected resolution conversations, particularly where the treating hospital or physician carries an occurrence policy with finite per-occurrence limits that a nuclear verdict would exhaust.
Virginia cases decided September 14, 2026 illustrate the breadth of exposure. A Prince William County jury returned a $2.65 million verdict for rectal injury caused by an incorrect incision during robotic-assisted surgery; a Campbell County jury awarded $2.2 million against a nursing home for negligent care the same day. Neither verdict approaches the nuclear threshold, but both reflect the willingness of Virginia juries to hold institutional defendants accountable at substantial dollar amounts.
Defense reserves are now calibrated to nuclear-verdict exposure even in cases with modest injury profiles, giving experienced plaintiff counsel more leverage in pre-trial mediation than the actual verdict risk alone would suggest.
Mass Tort MDL Update: Talc, PFAS, and the Bellwether Timing Problem
Three talc verdicts in a six-month span have reset expectations in MDL-2738. A Philadelphia jury awarded $250,000 in the Emerson estate case on February 13, 2026. A $32 million verdict followed on June 26, 2026. The largest single-plaintiff talc award to date came in December 2025 when a Baltimore jury returned $1.56 billion in a mesothelioma case against Johnson & Johnson. Plaintiff verdict ranges in talc cases now span five orders of magnitude, making aggregate resolution negotiations genuinely difficult for both sides.
The Bayer Roundup proceeding is at a different stage: the proposed $7.25 billion class settlement received preliminary approval in Missouri, with a final approval hearing scheduled post-July 2026. Plaintiff attorneys with Roundup-exposed clients who have not yet opted into the class should review CMO timelines promptly.
In AFFF PFAS MDL-2873 (D.S.C.), 23,573 total cases are on the docket, with 15,264 personal-injury claims pending as of September 2026. CMO 33 added liver cancer and thyroid cancer as compensable injury categories, expanding the eligible plaintiff pool. The next bellwether trial date remained under negotiation after the October 2025 date was vacated, reducing settlement pressure on remaining defendants including 3M and DuPont well below what the plaintiff bar would prefer.
AFFF counsel should note that CMO 33's expansion to liver and thyroid cancer warrants a re-screening of existing client files, as those diagnoses may have been recorded at intake without being connected to firefighting foam exposure.
Telehealth Standard of Care and the Ambulatory Surgery Center Liability Shift
Courts in Texas and Maryland are now applying the same negligence standard to remote providers that they apply to clinic-based providers. A July 2026 analysis confirmed this convergence: telehealth physicians face identical exposure to missed-diagnosis and medication-management claims as their in-person counterparts. The Department of Justice reinforced the criminal dimension of this trend in November 2025 when it convicted the founder of a digital-health platform for unlawful Adderall distribution, prompting plaintiff attorneys to revisit civil negligence theories in telehealth prescription cases that had previously been declined.
Separately, the migration of surgical procedures from hospital settings to ambulatory surgery centers is creating a distinct liability problem for plaintiffs. ASC institutional records, including credentialing files, equipment maintenance logs, and anesthesia protocols, are frequently thinner than hospital equivalents, which weakens the res ipsa environment. Informed-consent and credentialing theories are gaining traction as primary hooks in ASC cases precisely because they do not require the same depth of institutional documentation to support a liability finding.
Firms evaluating ASC-based surgical claims should request credentialing files and informed-consent records at intake, as these documents often provide the clearest path to liability where operative notes and nursing records are sparse.
ERISA Lien Preemption: The Settlement Calculation That Cannot Be Reduced by Equity
Self-insured employer health plans governed by ERISA are fully preempted from state made-whole reductions. This is not a recent development, but it remains an intake-checklist failure at firms that rely on common-law equitable doctrines to trim subrogation demands. When a plaintiff carries employer-sponsored health insurance through a self-insured ERISA plan, the plan's subrogation right is largely immune to state-law challenges, including the made-whole rule and common-fund doctrine reductions that work effectively against commercial insurers and Medicaid.
The practical consequence is significant. A plaintiff who receives a $400,000 settlement but carries a $175,000 ERISA subrogation claim may net considerably less than a comparable plaintiff covered by an HMO subject to state regulation. Firms that do not identify ERISA coverage at intake risk presenting clients with net recovery figures that require painful downward revisions at disbursement.
ERISA plan identification, specifically whether the employer is self-insured rather than fully insured, should be a mandatory intake field, not a diligence item deferred until after the settlement demand is filed.
Operations Note for Medical Providers Evaluating PI Case Participation
Medical providers evaluating participation in personal-injury cases need to understand the insurance market conditions driving the data above. When med-mal premiums are hardening and nuclear verdicts are setting record averages, carriers become more selective about which risk profiles they will defend, including the risk that a treating provider's records become a central exhibit in a product-liability or surgical-complication claim against a third-party defendant.
Providers participating in PI cases as treating physicians or lien holders should expect heightened scrutiny of billing documentation, treatment plans, and credentialing records, particularly in ASC settings where institutional oversight documentation is thinner. Maintaining clear contemporaneous records of medical necessity is the most reliable protection against both lien-reduction challenges and third-party subrogation disputes.
The question the plaintiff bar has not resolved: as ERISA preemption increasingly shields employer-plan subrogation demands from equitable reduction, does the residual negotiating pressure shift toward medical provider liens, and if so, what leverage do providers retain when plaintiff counsel needs to close a net recovery gap?